{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T21:00:07Z","timestamp":1785272407148,"version":"3.55.0"},"reference-count":19,"publisher":"Society of Nuclear Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.2967\/jnumed.123.265878","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T10:50:16Z","timestamp":1694083816000},"page":"1765-1771","source":"Crossref","is-referenced-by-count":6,"title":["Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of\n                    <sup>177<\/sup>\n                    Lu-PSMA I&amp;T"],"prefix":"10.2967","volume":"64","author":[{"given":"Amir","family":"Karimzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Soeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Feuerecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte-Sophie","family":"Hecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Knorr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias M.","family":"Heck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Tauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calogero","family":"DAlessandria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang A.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Rauscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2023,9,7]]},"reference":[{"key":"2026020205350913000_64.11.1765.1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.22742"},{"key":"2026020205350913000_64.11.1765.2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.clon.2018.11.001","article-title":"Treatment experiences, information needs, pain and quality of life in men with metastatic castrate-resistant prostate cancer: results from the EXTREQOL study","volume":"31","author":"Jenkins","year":"2019","journal-title":"Clin Oncol (R Coll Radiol)."},{"key":"2026020205350913000_64.11.1765.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026020205350913000_64.11.1765.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0"},{"key":"2026020205350913000_64.11.1765.5","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"177LuLu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet."},{"key":"2026020205350913000_64.11.1765.6","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"2026020205350913000_64.11.1765.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00186-6"},{"key":"2026020205350913000_64.11.1765.8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1055\/a-1234-5891","article-title":"Improving quality of life in patients with metastatic prostate cancer following one cycle of 177Lu-PSMA-617 radioligand therapy: a pilot study","volume":"59","author":"Marinova","year":"2020","journal-title":"Nuklearmedizin."},{"key":"2026020205350913000_64.11.1765.9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264402"},{"key":"2026020205350913000_64.11.1765.10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265346"},{"key":"2026020205350913000_64.11.1765.11","unstructured":"Fayers PM Aaronson NK. Bjordal K . The EORTC QLQ-C30 Scoring Manual. 3rd ed. European Organisation for Research and Treatment of Cancer; 2001."},{"key":"2026020205350913000_64.11.1765.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.139"},{"key":"2026020205350913000_64.11.1765.13","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1016\/j.clgc.2019.11.015","article-title":"Health-related quality of life and pain in a real-world castration-resistant prostate cancer population: results from the PRO-CAPRI study in the Netherlands","volume":"18","author":"Kuppen","year":"2020","journal-title":"Clin Genitourin Cancer."},{"key":"2026020205350913000_64.11.1765.14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.236414"},{"key":"2026020205350913000_64.11.1765.15","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41391-022-00569-8","article-title":"Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy","volume":"26","author":"van der Doelen","year":"2023","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"2026020205350913000_64.11.1765.16","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1007\/s00259-021-05237-y","article-title":"Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review","volume":"48","author":"Manafi-Farid","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026020205350913000_64.11.1765.17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00259-020-04797-9","article-title":"Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617: a WARMTH multicenter study (the 617 trial)","volume":"48","author":"Ahmadzadehfar","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026020205350913000_64.11.1765.18","first-page":"S626","article-title":"Health-related quality of life (HRQoL), pain and safety outcomes in the phase III VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer [abstract]","volume":"32","author":"Karim","year":"2021","journal-title":"Ann Oncol."},{"key":"2026020205350913000_64.11.1765.19","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1007\/s00259-019-04431-3","article-title":"Quality of life in patients with midgut NET following peptide receptor radionuclide therapy","volume":"46","author":"Marinova","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.123.265878","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:19:10Z","timestamp":1785269950000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.123.265878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,7]]},"references-count":19,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11,2]]},"published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.2967\/jnumed.123.265878"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.123.265878","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,7]]}}}